How to Start Semaglutide
Start subcutaneous semaglutide at 0.25 mg once weekly for the first 4 weeks, then titrate to 0.5 mg weekly for another 4 weeks, followed by 1 mg weekly if additional glycemic control or weight loss is needed, with the option to increase to 2.4 mg weekly for weight management or cardiovascular risk reduction. 1, 2
Subcutaneous (SC) Semaglutide Initiation
Standard Titration Schedule
The FDA-approved dosing follows a structured monthly escalation 2:
- Weeks 1-4: 0.25 mg once weekly
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1 mg once weekly (if additional glycemic control needed)
- Weeks 13-16: 1.7 mg once weekly (for weight management)
- Week 17+: 2.4 mg once weekly (maintenance dose for weight management)
For type 2 diabetes: The therapeutic doses are 0.5 mg or 1 mg weekly 3, 4. For obesity/weight management: Titrate up to 2.4 mg weekly 5, 6.
Flexible Titration Approach
Recent evidence suggests slower titration improves adherence and reduces gastrointestinal adverse events. A flexible 16-week titration starting at lower doses (0.0675 mg/week) with gradual weekly increases significantly reduced treatment discontinuation from 19% to 2% compared to standard titration 7. This approach allows delays for GI symptoms without compromising final efficacy.
Administration Details
- Timing: Administer once weekly at any time of day, with or without meals 1, 2
- Injection sites: Abdomen, thigh, or upper arm (similar exposure across sites) 2
- Steady state: Achieved after 4-5 weeks of once-weekly dosing 2
Oral Semaglutide Initiation
For oral formulation: Start at 3 mg once daily for 30 days, then increase to 7 mg daily, with option to escalate to 14 mg daily after another 30 days if additional glycemic control is needed 1, 8.
Critical Administration Requirements
- Take on empty stomach: At least 30 minutes before first food, beverage, or other oral medications
- Water restriction: Use no more than 120 mL (4 oz) of plain water only 1
- Bioavailability: Only ~1% (versus 89% for SC formulation), requiring absorption enhancer 9
Key Clinical Considerations
Minimizing Gastrointestinal Adverse Events
Gradual dose titration is essential to reduce nausea, vomiting, and treatment discontinuation 5. The most common adverse events are GI-related, with nausea occurring in approximately 40% of patients on liraglutide (a similar GLP-1 RA) 5.
If GI symptoms occur:
- Consider delaying dose escalation until symptoms resolve
- Clinical judgment should guide individual titration schedules 5
- If >2 consecutive doses missed: resume at same dose if previously well-tolerated, otherwise lower the dose
- If ≥3 consecutive doses missed: restart titration schedule 5
Renal Dosing
No dose adjustment required for any degree of renal impairment, including end-stage renal disease 3, 1, 2. This distinguishes semaglutide from some other GLP-1 RAs like exenatide (not recommended if CrCl <30) 1.
Concomitant Medications
When used with insulin or sulfonylureas:
- Reduce insulin or sulfonylurea dose to minimize hypoglycemia risk 3, 4, 5
- Monitor closely for hypoglycemia and counsel patients 5
Avoid combining with:
- Other GLP-1 receptor agonists
- DPP-4 inhibitors 5
Monitoring During Titration
Pre-initiation assessment:
- Ensure clinical stability (postpone if recent HF decompensation or arrhythmias) 10
- Baseline labs: kidney function, electrolytes, HbA1c 10
During titration (weeks 0-16):
- Monitor for GI symptoms at each dose increase
- Assess volume status if on diuretics or with renal impairment
- Check for hypoglycemia if on insulin/sulfonylureas 10
Long-term follow-up:
- Volume assessment every 3-6 months
- If <5% weight loss, consider alternative strategy
- Monitor for symptoms of pancreatitis, gallbladder disease 10
Contraindications
Absolute contraindications 3, 4:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- History of serious hypersensitivity to semaglutide
- Pregnancy or breastfeeding
Real-World Titration Patterns
Important caveat: Real-world data shows significant deviation from recommended titration schedules. Only 13% of patients reach maximum dose by their fifth prescription, and 33-48% remain on 1.0 mg dosing long-term 11, 12. Despite slower titration and lower maintenance doses than in trials, substantial weight loss (-13.6% at 12 months) is still achieved in those who continue treatment 12.
Discontinuation rates are high: Approximately 46-48% discontinue within 5-12 months, strongly associated with higher copayments and lower socioeconomic status 13, 12. This underscores the importance of addressing financial barriers and setting realistic expectations about long-term treatment.